Angiodynamics reports fiscal year 2024 third quarter financial results; updates fiscal year 2024 guidance to reflect asset divestiture

Latham, n.y.--(business wire)--angiodynamics, inc. (nasdaq: ango): fiscal year 2024 third quarter highlights completed the sale of its picc and midline product portfolios to spectrum vascular on february 15, 2024 discontinued its uniblate and starburst radiofrequency products, as well as its syntrax support catheter products, to further streamline its product portfolio   gaap as reported pro forma* net sales: $75.2 million $66.0 million growth: n/a 8.0% gross margin 47.7% 51.1% gaap loss per sh.
ANGO Ratings Summary
ANGO Quant Ranking